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G1/S transitionInsulin-like Growth Factor-1 (IGF-1) plays a key role in breast cancer development and cell cycle regulation. It
has been demonstrated that IGF-1 stimulates cyclin expression, thus regulating the G1 to S phase transition of
the cell cycle. Potassium (K+) channels are involved in the G1 phase progression of the cell cycle induced by
growth factors. However, mechanisms that allow growth factors to cooperate with K+ channels in order to
modulate the G1 phase progression and cyclin expression remain unknown. Here, we focused on hEag1 K+
channels which are over-expressed in breast cancer and are involved in the G1 phase progression of breast
cancer cells (MCF-7). As expected, IGF-1 increased cyclin D1 and E expression of MCF-7 cells in a cyclic
manner, whereas the increase of CDK4 and 2 levels was sustained. IGF-1 stimulated p21WAF1/Cip1 expression
with a kinetic similar to that of cyclin D1, however p27Kip1 expression was insensitive to IGF-1. Interestingly,
astemizole, a blocker of hEag1 channels, but not E4031, a blocker of HERG channels, inhibited the expression
of both cyclins after 6–8 h of co-stimulation with IGF-1. However, astemizole failed to modulate CDK4, CDK2,
p21WAF1/Cip1 and p27Kip1 expression. The down-regulation of hEag1 by siRNA provoked a decrease in cyclin
expression. This study is the ﬁrst to demonstrate that K+ channels such as hEag1 are directly involved in the
IGF-1-induced up-regulation of cyclin D1 and E expression in MCF-7 cells. By identifying more speciﬁcally the
temporal position of the arrest site induced by the inhibition of hEag1 channels, we conﬁrmed that hEag1
activity is predominantly upstream of the arrest site induced by serum-deprivation, prior to the up-regulation
of both cyclins D1 and E.ie Cellulaire et Moléculaire –
, 33 Rue St Leu, 80039, Amiens,
4.
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Ion channels, including potassium (K+) channels, are important in
the cell cycle and thus, in cell proliferation. They are found in a variety
of cancer cells [1–3].
It has been shown that Eag-1 K+ channels, a member of the
voltage-activated K+ channel superfamily, play a role in controlling
the proliferation and transformation of epithelial cells [1,4]. They
might be considered as potential markers for molecular staging and
targets for the development of anticancer therapeutic strategies [5].
Increased expression of Eag-1 channels is found in several cancer
types including breast cancer [6,7]. The inhibition of Eag-1 channelactivity suppresses the proliferation of breast cancer cells and
accumulates cells in G1 phase of the cell cycle [8,9]. Although no
direct evidence of themechanism has been provided, consequences of
the inhibition of K+ channels suggest that these channels may be
involved in the control of the cell cycle machinery, particularly the
regulation of cyclin-dependent kinase inhibitors (CDKI) and/or cyclin
expression [10,11].
The progression of cells through the cell cycle is regulated by
different cyclin/CDK complexes. These molecules form the regulatory
(cyclins) and catalytic (CDK, Cyclin-Dependent Kinase) subunits of cell
cycle-regulated kinase. After growth-factor stimulation, the ﬁrst cyclins
to appearwhen quiescent cells enter the cell cycle are theD-type cyclins
(D1, D2 and D3). D-type cyclins bind, and thereby activate, CDK4 and
CDK6. Activation of the cyclin D/CDK4–6 complex promotes G1 phase
progression. The sequential activationof the cyclin E/CDK2 complex and
hyperphosphorylationofpRb arenecessary for the release of the E2F (E2
promoter-speciﬁc factor) transcription factor leading to DNA synthesis.
Cyclins D and E are thus the main activators of the G1 to S phase
transition and therefore for the entry into S phase. The activity of the
cyclin/CDK complex can be inhibited by cyclin-dependent kinase
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cycle machinery. Indeed, p21WAF1/Cip1 and p27kip1 bind to cyclin/CDK
complexes and regulate theG1–S transitionby inhibition of the complex
activity [12].
In MCF-7 cells, cyclin D1 is the essential D-type cyclin [13,14] and
its role in the cell cycle progression is well established [15]. Both
cyclins D1 and E are overexpressed in several tumors including breast
cancer. In fact, cyclin D1 overexpression was reported in 30–60% of
primary ductal breast adenocarcinomas [16,17]. Different cyclin E
isoforms are overexpressed in 40% of breast cancers and are
associated with the tumor stage, grade and Ki67 proliferative index
[18,19].
IGF-1 is a strong mitogen factor for a wide variety of cancer cell lines,
including sarcoma, leukemia, prostate, breast, lung, colon, stomach,
esophagus, liver, pancreas, kidney, thyroid, brain, ovary, and uterus
cancers [20,21]. IGF-1 has been shown to regulate the expression of
cyclin, CDKproteins andRbproteinphosphorylationonbreast cancer cell
lines including MCF-7 cells. In serum-deprived MCF-7 cells, stimulation
by IGF-1, through thePI3Kpathway, enhances the expressionof cyclinD1
and cyclin E, hyperphosphorylation of pRb and subsequently, cell
proliferation [22].
We previously demonstrated that hEag1 K+ channels are involved
in the control of the cell cycle progression and proliferation of MCF-7
cells [8,9]. We also demonstrated that IGF-1 increased both the
activity and expression of hEag1 channels through a PI3-Kinase/Akt
dependent pathway [23]. Moreover, pharmacologically or more
speciﬁcally, the inhibition of hEag1 K+ channels by siRNA decreased
the mitogenic effect of IGF-1 on MCF-7 cells.
In this study, we more thoroughly investigated the involvement of
hEag1 K+ channels in the G1 phase progression and determined
whether or not these channels could be implicated in the IGF-1
regulation of cyclin (D1, E), CDK (4, 2), or CDKI (p21WAF1/Cip1, p27kip1)
expression. This study is the ﬁrst to demonstrate that the hEag1 K+
channel is a key actor of the IGF-1 pathwaywhichmodulates cyclin D1
and E expression, leading to G1 progression and S phase transition
and therefore, cell proliferation.
2. Material and methods
2.1. Cell culture
The MCF-7 breast cancer cell line was obtained from the American
Type Culture Collection. MCF-7 cells were grown in Eagle's Minimum
Essential Medium (EMEM; Gibco) supplemented with 5% fetal bovine
serum (FBS), L-glutamine (2 mM), and gentamicin (50 μg/ml)
(Gibco). Cells were maintained at 37 °C in a humidiﬁed atmosphere
with 5% CO2.
To obtain cells accumulated in G1 phase, cells were incubated in
serum- and phenol red-free EMEM medium for 24 h [8,9]. This
environment was used as the control condition in all our experiments
to study the effects of IGF-1. Cells were then stimulated with IGF-1
(20 ng/ml) to enter the cell cycle.
2.2. Temporal position of the synchronized site in G1 phase
To determine the temporal position of the arrest site in G1 phase
induced by astemizole and lovastatin, MCF-7 cells were grown in
EMEMmediumwith 5% FBS for 48 h and then treated with astemizole
(5 μM) (Sigma, France) or lovastatin (20 μM) (Sigma, France) for 48 h
and 39 h respectively. After treatment, themediumwas replaced with
drug free-EMEM medium to resume cell progression in the cell cycle.
2 mM of mevalonic acid (Sigma, France) was added in the medium to
reverse the effect of lovastatin. After different times of removal, the
cells were then harvested and the cell distribution in the cell cycle was
measured by ﬂow cytometry.2.3. Flow cytometry
Cell cycle analysis was performed by measuring cellular DNA
content by ﬂow cytometry. Cells were collected by trypsinization,
resuspended in 300 μl PBS-EDTA (5 mM) and ﬁxed with 700 μl
absolute ethanol. After ﬁxation, cells were pelleted by centrifugation,
resuspended in PBS-EDTA (5 mM), treated with ribonuclease at a ﬁnal
concentration of 10 μg/ml (Sigma, France) for 30 min and stainedwith
propidium iodide (Sigma, France) at a ﬁnal concentration of 50 μg/ml.
To assess cell cycle distribution patterns (G0/G1, S and G2/M phases),
the stained samples were measured using a ﬂow cytometer (Elite
Beckman/Coulter, USA).2.4. Western blotting analysis
Treated cells were washed twice in the phosphate buffered saline
(PBS), lysed in Laemmli's buffer (Tris-base 62.5 mM pH 6.8, glycerol
10%, 2-βmercaptoethanol 5%, SDS 2.3% and 0.025% of bromophenol
blue) and heated three times to 95–100 °C for 10 min. The lysate was
analyzed by immunoblotting. Equal amounts of protein were
separated by electrophoresis on SDS-PAGE and electrotransferred to
a nitrocellulose membrane. Blots were blocked in 5% nonfat milk for
1 h and then incubated overnight at 4 °C in Tris-buffered saline
containing Tween 20 (0.1%) (TBS-T) with a primary antibody directed
against either cyclin D1 (DS26, 1:500), p21Waf1/Cip1 (12D1, 1:500),
p27Kip1 (1:500), phospho-Rbser807/811 (ppRb ser807/811) (1:500),
protein Rb (pRb) (4H1, 1:1000, Cell Signaling Technology), CDK4
(C-22, 1:1250), cyclin E (C-19, 1:1300), CDK2 (M2, 1:2000), or actin
(used as an internal standard) (C-11, 1:2000, Santa Cruz Biotechno-
logy). Membranes were washed three times in TBS-T and then
incubated with horseradish peroxidase-conjugated secondary anti-
body for 1 h at room temperature. After three washes in TBS-T, the
immuno-reactive bands were detected using the ECL chemilumines-
cent system (Amersham-Biotech), visualized with the ChemiDoc XRS
system (Biorad) and quantiﬁed using the Quantity One software
(Biorad).2.5. siRNA cell transfection
The hEag1 siRNA sequence used was 5′-CUGGACAUGGACCAA-
GUGGAC(dTdT)-3′ (positions 1578–1598 on the hEag1a sequence and
positions 1659–1679 on the hEag1b sequence, accession numbers
AF078741 and AF078742, respectively) as described by Weber et al.
[24]. Control experiments were performed by transfecting a func-
tional non-coding siRNA as a negative control (Dharmacon Research
Inc., USA). 2×106 MCF-7 cells were transfected using a Nucleofector
device and the corresponding kit (Amaxa Inc., Germany). Transfection
protocols were performed following the manufacturer's instructions
(program E-014; solution V). Using the nucleofection technique,
Gresch et al. [25] reported that the nucleofection by 1 μM siRNA is
efﬁcient, optimal and without non-speciﬁc effects up to 5 μM. Based
on these results, we chose to use hEag1 siRNA (si hEag1) at 2 μg
(equivalent to 1.3 μM). Immediately after transfection, cells were
cultured in EMEM medium with 5% FBS. After treatment, cells were
then prepared for immunoblotting studies.2.6. Drugs and plasmids
For all experiments, MCF-7 cells were activated with recombinant
human IGF-1 (Promocell GmbH). Astemizole (AST) (Sigma, France)
was used as a blocker of hEag1 channels and E-4031 (Sigma, France)
as a speciﬁc blocker of HERG channels. The ﬁnal concentration of
DMSO was ≤1/1000.
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Data are presented as mean±SD. Averages of the kinetics were
tested with a one-way ANOVA followed by the Dunnett post-test
(control was the 0 h point). Differences between the values were
considered signiﬁcant when pb0.05. The p values of b0.05, b0.01 and
b0.001 are represented as *, ** and *** respectively.
3. Results
3.1. Effect of IGF-1 on both the cell cycle phase distribution of MCF-7 cells
and cell cycle protein expression
MCF-7 cells, in serum- and phenol red-deprived medium for 24 h,
were growth-arrested in G1 phase [8]. The addition of IGF-1 induced a
cohort of cells to re-enter the cell cycle [26]. In these conditions, we
observed the relationship between the cell cycle position and cyclin
gene expression induced by IGF-1 in MCF-7 cells. First, we determined
the time required for serum- and phenol red-deprived MCF-7 cells to
exit from the G1 phase and enter into S phase after IGF-1 stimulation.
In order to do this, cells were harvested after IGF-1 treatment at
different incubation times for DNA analysis by ﬂow cytometry. Fig. 1
shows that after 8 h of IGF-1 stimulation, the proportion of cells in G1
phase began to decrease, whereas the proportion in S phase
simultaneously began to increase. The cell distribution in S phase
was clearly modiﬁed after 12 h of incubation and became higher after
14 h. These results indicate that the time required for cells to exit from
the G1 phase and enter into S phase was between 8 and 10 h after the
addition of IGF-1. After 14 h of stimulation, the cell rate was at its
maximum in S phase. Next, we studied the expression pattern of the
key proteins in G1 and S phase induced by IGF-1 in this time interval.
MCF-7 cells were cultured in the same culture condition as above. The
levels of these proteins were determined by Western blotting. Our
results show that IGF-1 increased the cyclin D1 level with a maximum
observed after 4–6 h of stimulation (~two-fold). This effect wasFig. 1. Timecourseof IGF-1 effect on thedistribution in cell cycle of serum-deprivedMCF-7
cells.MCF-7 cellswere arrested inG1phase by serum- andphenol red-deprivation for 24 h
(Time=0). To determine the time required to emerge from G1 phase and enter into S
phase by the addition of IGF-1 (20 ng/ml), cells were stimulated with IGF-1 and collected
at the indicated times. Cells were then stainedwith propidium iodide, and ﬂow cytometry
was used to determine thepercentageof cells inG0/G1, S andG2/Mphases at the indicated
times. Top, each point represents the mean±SD from three experiments. Bottom,
representative distribution of cells in the cell cycle at three deﬁned points of the kinetic
(a, b and c).sustained until 10 h andwas abolished at 12 h of stimulation (Fig. 2A).
The highest expression for cyclin E was obtained at 8–10 h of IGF-1
incubation (~two-fold) as the cells entered in S phase, and then
declined after 14 h (Fig. 2B). IGF-1 also enhanced the expression of
CDK4 and CDK2 after 4 and 8 h of stimulation, respectively (Fig. 2A
and B). As expected, IGF-1 increased cyclin D1 and E expression in a
time- and cyclic-dependent manner. On the other hand, the
modulation of the catalytic subunits by IGF-1 was sustained over
time. Moreover, no modulation of the p27kip1 protein level by IGF-1
was observed (Fig. 2C). In contrast, IGF-1 stimulation resulted in an
increase in the p21Waf1/Cip1 protein level in the same kinetic as cyclin
D1 (Fig. 2C).
3.2. Involvement of hEag1 channels in the up-regulation of cyclin D1 and
E expression by IGF-1
To determine if hEag1 channels are involved in the up-regulation of
G1 and S phase key proteins induced by IGF-1, we treated serum- and
phenol red-deprivedMCF-7cellswith20 ng/mlof IGF-1orpre-incubated
30 minwith astemizole (5 μM) and treated in the presence of both IGF-1
and astemizole. Cells were harvested at the indicated times and the cell
cycle proteins levelswere analyzedbyWesternblotting. After 4 hand6 h
of both IGF-1 and astemizole treatment, we observed an increase of
cyclins D1 and E, respectively, leading to entry into the cell cycle
(Fig. 3Aa–b and Ba–b). This was conﬁrmed by a FACs analysis
(Supplemented data 1) which showed that the astemizole treatment
did not affect the distribution of cells in the cell cycle phases after 24 h.
However, we detected a signiﬁcant decrease in cyclin D1 and cyclin E
expression after 6 h and 8 h of astemizole treatment respectively
(Fig. 3ABa–b). This decrease was maintained until 48 h. Moreover, at
48 h, in the presence of astemizole, the results show that the cyclin D1
protein level was signiﬁcantly lower than the control condition (serum-
deprivation) (Fig. 3A-a) and that MCF-7 cells were arrested in G1 phase
(supplemented data 1). We also detected that the inhibition of cyclin
expression was accompanied by a strong decrease of Rb protein
phosphorylation after 48 h of IGF-1 and astemizole treatment, demon-
strating the lack of cyclin/CDK complex activity (Fig. 3C). However,
astemizole failed to modulate the CDK4, CDK2, p21Waf1/Cip1 and p27kip1
protein levels (supplementeddata 2). Taken together, our results suggest
that the inhibition of hEag1 channels: i) triggered an inhibition of cyclin
D1 and E expression leading to their faster turn-over, and ii) induced a
decrease of cyclin D1 expression below its level in serum-deprived cells.
Therefore, we concluded that the astemizole-induced cell cycle arrest of
MCF-7 is managed by the down-regulation of cyclin.
Astemizole has also been known to block HERG potassium
channels [27,28]. To test the implication of these channels in the
regulation of cyclin expression, we used a speciﬁc HERG channel
blocker (E-4031). E-4031 at 1 μM is known to speciﬁcally block HERG
channel activity. We used this inhibitor in the same conditions as
described for the astemizole treatment. Our results show that after 8 h
of treatment, E-4031 had no effect on the cyclin D1 and E protein
levels, whereas in the presence of astemizole, cyclin D1 and E
expression was decreased (Fig. 4A). These results suggest that hEag1
channels, but not HERG channels, contributed to the regulation of
cyclin expression.
To conﬁrm these results, we used siRNA technology to more
speciﬁcally down-regulate hEag1 channel expression. MCF-7 cells
were thus transfected with hEag1 siRNA using the Nucleofector
technology. The effect of hEag1 siRNA (si hEag1) was compared to
transfected cells with control siRNA (see the Material and methods
section). After transfection, cells were incubated in culture medium
for 48 h and then serum- and phenol red-deprived for 24 h. Cells were
harvested either after this treatment or after 8 h of IGF-1 stimulation.
Fig. 4B shows that transfection with si hEag1 reduced cyclin D1 and E
protein levels as compared to the control siRNA, either in the presence
or absence of IGF-1. Altogether, our results clearly show that the effect
Fig. 2. Effect of IGF-1 on the expression of G1 and S phase key proteins. MCF-7 cells were serum- and phenol red-deprived for 24 h (Time=0) and then stimulated with IGF-1 (20 ng/
ml). Cells were harvested at the indicated times and lysed in Laemmli's buffer. Cell lysates were analyzed byWestern blotting using primary antibodies directed against cyclin D1 and
CDK4 (A), cyclin E and CDK2 (B), p21Waf1/Cip1 and p27Kip1 proteins (C). For each protein, a representative immunoblot of three independent experiments is shown (left panel).
Protein levels were quantiﬁed and normalized to actin. The indicated values are the mean±SD of three independent experiments (right panel). *pb0.05; **pb0.01.
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cyclin D1 and E expression.3.3. Determination of the temporal position of the arrest site induced by
hEag1 channel inhibition
In order to clarify the involvement of hEag1 channels in G1 phase,
we speciﬁcally studied the temporal position of the arrest site induced
by astemizole in G1 phase using ﬂow cytometry. As astemizole is
reversible [29], MCF-7 cells resume their progression through the cell
cycle after removal of this drug. We thus estimated the time required
for MCF-7 cells to exit the arrest site in G1 phase and enter into S
phase. To locate the site of arrest by astemizole, we compared the
temporal properties of arrest induced by astemizole with that of arrest
induced by either serum- and phenol red-deprivation (Fig. 1) or
lovastatin. Lovastatin is well known to block the cells in early G1 phase
[30,31]. Lovastatin inhibits 3-hydroxy-3methylglutaryl coenzyme A
reductase and its effect is rapidly reversed by the addition of mevalonic
acid (2 mM) to the culturemedium.MCF-7 cellswere thus arrested inG1
phase by lovastatin (20 μM) treatment for 39 h. After removal of
lovastatin by the addition of mevalonic acid, we demonstrated that
MCF-7 cells exited the lovastatin arrest site and entered into S phase after
an 18–20 h lag period. The number of cells in S phase peaked at 24–26 h
after drug removal and then began to decrease, in correlation with anincrease in the number of cells in G2/M phase (Fig. 5A). Therefore, we
estimated that the duration of G1 phase was approximately 20 h long.
Afterwards, we determined the temporal position of the arrest site
induced by astemizole. Cells were treated with astemizole (5 μM) for
48 h. After treatment, themediumwas replacedwith drug-free EMEM
medium. Cell growth was restored and no effect was observed on cell
mortality (data not shown). Our results clearly demonstrate that the
release of MCF-7 cells from the arrest site by astemizole entered into
S phase between 10 and 12 h, and that the number of cells in S phase
peaked at 16 h after drug washout (Fig. 5B). When these data are
considered together, we showed that after drug removal, lovastatin-
treated cells needed 18–20 h to enter into S phase (Fig. 5A),
astemizole-treated cells needed 10–12 h (Fig. 5B) and serum-
deprived cells needed 8–10 h (Fig. 1). Our results suggest that the
arrest site induced by astemizole is upstream of the arrest site induced
by serum-deprivation but downstream of the early arrest site induced
by lovastatin. We thus conﬁrmed that hEag1 activity occurs in mid-G1
phase, prior to the up-regulation of both cyclins D1 and E.4. Discussion
IGF-1 is known as an inductor of the cell cycle by inducing the
cyclin and CDK expression. Although its biological effect on the cell
cycle machinery is well known, the contribution of ionic channels has
Fig. 3. Astemizole treatment prevented the IGF-I-induced upregulation of cyclin D1 and E protein levels. Serum and phenol red-deprived MCF-7 cells were stimulated with 20 ng/ml
of IGF-1 or pre-incubated 30 minwith astemizole (5 μM) and treated in the presence of both IGF-1 and astemizole. Cells were harvested at the indicated times and the levels of cyclin
D1 (A) and cyclin E (B) were analyzed by Western blotting. a: A representative immunoblot of three experiments is shown. b: Kinetics showing the evolution of the cyclin levels in
both conditions. Protein levels were quantiﬁed and normalized to actin. The variation in the protein level between the IGF-1 treatment and IGF-1+astemizole treatment was
statistically assessed for each point of the kinetics. The indicated values are the mean±SD of ﬁve independent experiments. *pb0.05; **pb0.01. C: A representative immunoblot of
the effect of hEag1 inhibition on phosphorylated Rb protein (ppRb) vs Rb protein (pRb).
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elucidate the involvement of a class of K+ channels known to be
involved in controlling breast cancer cell cycle progression, and which
is regarded as a tumormarker, in the regulation of hEag1 K+ channels.
In MCF-7 cells, IGF-1 treatment increased cyclin D1, cyclin E and
p21Waf1/Cip1 protein levels in a cyclic-dependent manner but did not
modulate p27kip1 expression, a typical expression pattern of the
proliferation response to diversemitogenic growth factors. These results
are consistent with well known mechanisms describing cell cycle
machinery regulation by IGF-1 in MCF-7 cells [22,32,33]. p21Waf1/Cip1,
originally identiﬁed as an inhibitor of the cyclin/CDK complexes, has also
been shown to have a role as an adaptor protein that assembles and
promotes the kinase activity of cyclin D/CDK4 complexes [34] and thus,
is acknowledged as a positive regulator in the cell proliferation induced
by IGF-1 inMCF-7 cells [32]. As it iswell known that the activity of cyclin
D1/CDK4 and cyclin E/CDK2 complexes are optimal during late G1 phase
and at the G1/S transition, the time course for the expression of these
different proteins correlates with our results on the IGF-1-induced cell
redistribution of the cell cycle. Moreover, we show that the CDK4 and
CDK2 protein levels were markedly and sustainably increased in
response to IGF-1 treatment. The induction of CDK protein levels is not
restricted to IGF-1 stimulation because it was also observed after
treatmentwith other potent breast cancermitogens, such as insulin [35].
In 1996, Wonderlin and Strobl [11] showed that K+ channels are
involved in the ﬁrst events of G1 phase, and thus suggested that their
activity shouldbenecessary to the establishmentof theevents preceding
DNA synthesis. The up-regulation of cyclinsD1andEby growth factors is
the ﬁrst event prior to the entry of cells into S phase. In 2001 and 2004,
our group proposed hEag1 K+ channels as an initiating actor of G1 phase[8,9]. It is for this reason that we studied the effect of hEag1 channel
inhibition on IGF-1-regulation of cyclin expression.
In the presence of astemizole or siRNA, the amount of cyclin D1 is
signiﬁcantly reduced after treatment. After 48 h of hEag1 channel
inhibition, we observed a decrease of cyclin D1 expression, which was
accompanied by a strong decrease of Rb phosphorylation and an
arrest of the cell cycle in G1 phase. Cyclin D1 is reported as being an
important regulator of cell cycle initiation. The crucial role of cyclin
D1/CDK4 in G1 phase progression inMCF-7 cells is suggested since the
inhibition of cyclin D1 expression by antibodies or siRNA resulted in
hypophosphorylation of Rb protein, G1 arrest and cell proliferation
inhibition [15,36]. Our results show that hEag1 channel inhibition: (i)
induced a signiﬁcant decrease of an important actor involved in cell
cycle initiation, and (ii) produced similar results to cyclin D1
inhibition. Moreover, the effect of hEag1 channel inhibition is
accompanied by a decrease of cyclin E expression, the key regulator
of the G1/S transition and necessary for the entry of cells into S phase.
Astemizole treatment produced a signiﬁcant decrease of cyclin D1
after 6 h. The protein level is always the sum of synthesis and
degradation. Therefore, it may be hypothesized that either synthesis
was slowed down or degradation increased. The half-life time of
cyclin has been shown to be quite short, at approximately 45 min [37].
Furthermore, we demonstrated that the decrease of cyclin D1
expression occurred until 48 h of treatment. Therefore, this strong
decrease of cyclin D1 after 6 h of astemizole treatment is likely due to
the inhibition of cyclin D1 synthesis induced by hEag1 blockage.
According to the literature, the ﬁrst 4 h of cyclin D1 expression is
sufﬁcient to trigger cell cycle entry, which is why the cell starts cycling
even in the presence of astemizole [35]. This also suggests that the
Fig. 4. Involvement of hEag1 channels in cyclin D1 and E expression. (A) After cells were serum- and phenol red-deprived for 24 h, they were then stimulated with 20 ng/ml of IGF-1
or pre-incubated 30 min with either astemizole (5 μM) or E-4031 (1 μM), a speciﬁc blocker of HERG channels, and then treated by IGF-1 in the presence of astemizole or E4031 for
8 h. The cyclin D1 and E protein levels were determined by Western blotting. The results shown are representative of the two independent experiments. (B) MCF-7 cells were
transfected by a Nucleofector device with either control siRNA (Si control) or hEag1 siRNA (Si hEag1), and then cultured in EMEMmediumwith 5% FBS. After 48 h, cells were serum-
and phenol red-deprived and then stimulated with IGF-1 (20 ng/ml). The cyclin D1 and E protein levels were analyzed after 24 h of serum- and phenol red-deprivation and after 8 h
of IGF-1 stimulation. For each experiment, a representative immunoblot of three independent experiments is shown (left panel). Protein levels were quantiﬁed and normalized to
actin. The indicated values are the mean±SD of three independent experiments (right panel). NS = not signiﬁcant result; *pb0.05.
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phenomenon (more than 4 h).
After 48 h of astemizole treatment, we observed that the decrease
of cyclin D1 expression is below its level in serum-deprived cells. We
thus hypothesized that the hEag1 channel control of the cell cycle
would be upstream of the G1 phase synchronization by serum
deprivation, since the cyclin D1 protein level is lower in early G1
phase events. Bymore speciﬁcally identifying the temporal position of
the arrest site induced by the inhibition of hEag1 channels, we
demonstrated that the arrest site induced by astemizole is upstream
of the arrest site induced by serum-deprivation but downstream of
the early arrest site induced by lovastatin. We thus conﬁrmed that
hEag1 activity occurs upstream of the up-regulation of both cyclins D1
and E. Taken together, this study is the ﬁrst to demonstrate the
importance of hEag1 K+ channel activity in the events preceding DNAsynthesis, namely IGF-1-induced expression of cyclin D1, E and as a
result, pRb phosphorylation.
Few studies have established a link between K+ channel activity
and the machinery of the cell cycle. Treatment by pharmacological
inhibitors of K+ channels (TEA, 4-AP) failed to modulate the increase
in the expression of cyclin D induced by PDGF after 6, 12 and 18 h of
treatment, but increased the expression of p27kip1 and p21Waf1/Cip1
after 48 h of treatment [10,38]. Similar results were obtained when the
membrane potential was depolarized by increasing extracellular K+. The
authors proposed that changes in the membrane potential (depolariza-
tion) could activate a signaling pathway involving the p27kip1 and
p21Waf1/Cip1 proteins. Recently, Soriani et al. [39,40] reported an
accumulation of cells in G1 phase, an accumulation of the p27kip1 protein
and a reduction in cyclin A expression when they blocked K+ channels.
They proposed that the inhibition of K+ channels induced a deterioration
Fig. 5. Temporal position of the arrest site by a hEag1 channel blocker. To determine the
temporal position of the arrest site induced by astemizole, we used lovastatin as a
control condition for early G1 phase synchronization. MCF-7 cells were thus arrested in
G1 phase by either lovastatin (20 μM) (A) or astemizole (5 μM) (B) treatment for 39 h
and 48 h, respectively. The medium was replaced with drug free-EMEM medium after
astemizole treatment or replaced with drug free-EMEM medium supplemented with
2 mM mevalonic acid after lovastatin treatment (Time=0). Cells resumed their
progression into the cell cycle and were then collected at different times after wash out
of these drugs, as indicated. After staining with propidium iodide, the cell distribution
in G0/G1, S and G2/M phases was examined by ﬂow cytometry. Top, each point
represents the mean±SD from the three experiments. Bottom, a representative
distribution of the cells in the cell cycle at three deﬁned points of the kinetic (a, b and c).
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accumulation of the protein p27kip1. In our study, the absence of a
correlationbetween the inhibition of hEag1 channels and accumulation of
the p27Kip1 protein suggest that the accumulation of cells in G1 phase is
not due to this kind of process.Moreover, Roy et al. [27] reported the non-
involvementof thehEag1channel in cell volumeregulation inMCF-7cells,
in contrast to the human ether-a-go-go related channels (HERG), whose
involvement has been demonstrated using a speciﬁc blocker, E-4031.
However, we did not detect any effect on cyclin expression following E-
4031 treatment. Finally, it has been proposed that the deterioration of cell
volume induced by K+ channel inhibitors could alter the activity and
concentrationof all cellular compounds involved inproliferativeprocesses[41]. In the presence of the astemizole treatment, p21Waf1/Cip1 and CDK
expression did not appear to be modiﬁed. These results strengthen the
hypothesis that hEag1 channels seem to be involved in a more speciﬁc
pathway regulating cyclin expression.
InMCF-7cells, theprincipal effectorof cyclinD1 inductionby IGF-1 is
the Akt protein [22]. The involvement of ion channels in the regulation
of Akt phosphorylation has been reported. In fact, the phosphorylation
rate of Akt was strongly dependent on the extracellular calcium
concentration. A reduction in this concentration to 0.3 mM strongly
decreases the phosphorylation of this protein [42,43].
Moreover, it has been well established that the progression of cells
through G1 requires calcium events [44,45]. Different calcium actors
have been identiﬁed as participating in these processes [46,47].
Furthermore, available evidence suggests that Ca2+-dependent path-
ways are required prior to the activation of cyclin D/CDK4 and pRb
hyperphosphorylation [48]. Potassium channel activity might inﬂuence
mitogenic Ca2+ signals by providing andmaintaining a sufﬁcient driving
force for Ca2+ entry [49,50]. In our previous works, we reported that the
inhibition of hEag1 channels reduces the concentration of intracellular
calcium in synchronized cells in G1 phase [9]. Considered together, we
can suggest that the inhibition of hEag1 channels could disturb calcium
homeostasis, leading to a reduction of Akt phosphorylation and thus to a
decrease of cyclin D1 and E levels induced by IGF-1.
In conclusion, our study brings new elements towards the
understanding of the function of hEag1 channels and may lead to the
development of ion channel targeted cancer therapy through IGF-1
modulation.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.01.025.
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